Genetic background affects susceptibility to pancreatic ductal adenocarcinoma in the Ela-KRAS G12D mouse model. In this model, KRAS oncogene expression is driven by an elastase promoter in acinar cells of the pancreas on an FVB/NTac (FVB) background [FVB-Tg(Ela-KRAS G12D )] with the transgene carried on the Y chromosome. Through linkage analysis of crosses between the C57BL/6J (B6), BALB/cJ (BALB), and DBA/2J (D2) inbred strains of mice and resistant FVB-Tg(Ela-KRAS G12D ), we have identified six susceptibility loci that affect mean preinvasive lesion multiplicity. Markers on chromosome 2 segregated with high tumor multiplicity in all three strains; these loci were designated Prsq1-3 (pancreatic ras susceptibility quantitative trait loci 1-3; combined F2 and N2 LOD W , 6.0, 4.1, and 2.7, respectively). Susceptibility loci on chromosome 4, designated Prsq4 and Prsq5, were identified in crosses between FVB transgenic mice and B6 or BALB mice (combined F2 and N2 LOD W , 3.6 and 2.9, respectively). A marker on chromosome 12 segregated with tumor multiplicity in a BALB × FVB-Tg(Ela-KRAS G12D ) cross and was designated Prsq6 (LOD W , ∼2.5). B6-Chr Y FVB-Tg(Ela-KRASG12D) and BALB-Chr Y FVB-Tg(Ela-KRASG12D) consomics, which carry the KRAS transgene on the FVB Y chromosome on an otherwise inbred B6 or BALB background, developed ∼4-fold (B6) and ∼10-fold (BALB) more lesions than FVB-Tg(Ela-KRAS G12D ) mice. By 12 months of age, 10% of BALB-Chr Y FVB-Tg(Ela-KRASG12D) mice developed invasive carcinomas. Our findings provide evidence that regions of chromosomes 2, 4, and 12 influence the development and progression of pancreatic neoplasms initiated by an oncogenic allele of KRAS in mice. Cancer Res; 70(21); 8398-406.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most common cancer of the pancreas in humans. It is the fourth leading cause of cancer-related death in the United States, although it represented only 3% of the total cancer cases reported in 2009 (1) . Survival once the cancer is diagnosed is low, with median survival of <6 months, and ∼3% to 5% of patients surviving 5 years (1) . Few and often vague symptoms precede PDAC. Consequently, patients commonly present with jaundice at the time of diagnosis, indicating advanced disease that is metastatic, and difficult to treat (2) . Development of PDAC is influenced by a combination of genetic events (somatic mutations) and nongenetic events (tissue damage) in humans as well as in animal models (3, 4) . Activating mutations of the KRAS oncogene, which can be found in >90% of PDAC (5) , as well as inactivating mutations of the tumor suppressor genes CDKN2A, TP53, and SMAD4, have been identified (3). These alterations accumulate over time and are associated with progression of the disease through consecutive stages of pancreatic intraepithelial neoplasia (PanIN; refs. [6] [7] [8] .
In the late stages of PDAC, identification of the potential roles (if any) of the many mutations that have accumulated becomes very difficult. The creation of mouse models to investigate the multistep progression model has greatly expanded our knowledge (9, 10) . The diverse genetically engineered models, which use a variety of promoters to target multiple exocrine cell types, cause a spectrum of pathologic changes that mimic various aspects of the human disease (11) . These models have provided evidence that activated KRAS might be an initiating genetic event, and that it cooperates with CDKN2A and TP53 deficiency to cause progression to metastatic disease (9) (10) (11) (12) .
KRAS is a member of the RAS family of oncogenes involved in the signaling pathways of many receptor tyrosine kinases. The mutations most commonly seen in PDAC, substitution of either valine or aspartate in place of glycine at codon 12, mimic the GTP-bound form or active conformation of KRAS (13) (14) (15) . A transgenic mouse model directing oncogenic KRAS activity to the pancreas, Ela-KRAS G12D , has been generated on an FVB inbred genetic background and described previously (16) . The elastase promoter sequence directs expression of human KRAS G12D specifically to the acinar cells of the exocrine pancreas. Animals harboring this transgene have normal pancreases at birth, but by 1 month, multiple focal preneoplastic lesions are observed. Adult mice display acinar-to-ductal metaplasia and preinvasive ductal lesions.
We crossed Ela-KRAS G12D mice with several divergent inbred strains to identify genetic modifiers that affect the multiplicity and progression of pancreatic lesions. We report the discovery, through linkage analysis, of the pancreatic ras susceptibility quantitative trait loci 1-6 (Prsq1-6). These loci regulate the risk for formation and progression of pancreatic ductal neoplasms.
Materials and Methods

Mice
C3H/HeJ (C3), SWR/J (SW), C57BL/6J (B6), DBA/2J (D2), and BALB/cJ (BALB) inbred strains were obtained from The Jackson Laboratory. FVB/NTac mice were obtained from Taconic. FVB-Tg(Ela-KRAS G12D ) transgenic mice [FVB-TgN (Ela1Kras*G12D)9EPS], which carry the transgene on the Y chromosome, were described previously (16) . All mice were used in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All experimental protocols were approved by the Animal Care and Use Committee of the University of Wisconsin-Madison. Mice were housed in plastic cages on corncob bedding (Bed O'Cobs, Anderson Cob Division). Mice used in the initial F1 study ( Supplementary Table S1 ) and those bred and maintained for subsequent linkage and consomic studies (Tables 1-3) were housed and analyzed in separate facilities. Mice used in the linkage studies were fed Wayne Breeder Blox (11% fat; Continental Grain), whereas consomic mice were fed Mouse Diet 9F 5020 (LabDiet). All mice were given acidified tap water ad libitum. Animal health was monitored by daily inspection.
Phenotype analysis
To determine the influence of the genetic background of Ela-KRAS G12D mice on pancreatic lesion multiplicity, FVB-Tg(Ela-KRAS G12D ) male transgenic mice were crossed with C3, SW, B6, D2, and BALB inbred strain females to produce F1 progeny. These strains were chosen to provide a genetically diverse pool for the identification of potential modifier genes (17) . Pancreatic lesion multiplicity of F1 progeny was determined at 14 months of age. To map modifier loci in Ela-KRAS G12D mice, F1 progeny from crosses between FVB transgenic and B6, D2, or BALB mice were mated to create intercross (F2) mice (FVB × B6, FVB × D2, and FVB × BALB). The F1 progeny were also backcrossed to the FVB parental strain to create backcross (N2) progeny. F2 and N2 progeny were analyzed for pancreatic lesion multiplicity at 12 months of age. Consomic mice carrying the FVB-Tg(Ela-KRAS G12D ) Y chromosome were created by backcrossing to B6 (N17) and BALB (N11) inbred backgrounds, and pancreatic lesion multiplicity was determined at 12 months of age.
Mice were euthanized by CO 2 asphyxiation. Pancreases were collected and fixed in Carnoy's solution for 1 hour and then transferred to 70% ethanol. After fixation, pancreases were bisected and paraffin embedded, sectioned to the first "full face" of pancreatic tissue, mounted on a slide, and stained with H&E for microscopic examination. Slides were then examined using an Olympus BX40 microscope at ×100 magnification, and ducts containing irregular epithelial cells (16) were enumerated. Slide section areas were analyzed with ImageJ v1.42 software (18) .
Genotyping
DNA was isolated from tails (modifier study and linkage analysis) or toes (consomics) using a standard proteinase Table 1 . Pancreatic lesion multiplicity of Ela-KRAS G12D mice at 12 mo of age is increased in crosses between FVB and B6, D2, or BALB
Mouse strain
No. mice Lesion multiplicity ± SD FVB-Tg(Ela-KRAS G12D ) 25 1.6 ± 1.5 B6FVB-Tg(Ela-KRAS G12D )F1 35 14.9 ± 6.6* D2FVB-Tg(Ela-KRAS G12D )F1 34 14.1 ± 5.8* BALBFVB-Tg(Ela-KRAS G12D )F1 30 11 ± 15* B6FVB-Tg(Ela-KRAS G12D )F2 76 12.1 ± 9.9* D2FVB-Tg(Ela-KRAS G12D )F2 74 18 ± 19* BALBFVB-Tg(Ela-KRAS G12D )F2 78 15 ± 13* FVB(B6FVB-Tg(Ela-KRAS G12D )) N2 52 8.9 ± 9.1 † FVB(D2FVB-Tg(Ela-KRAS G12D )) N2 54 7.8 ± 5.6 † FVB(BALBFVB-Tg(Ela-KRAS G12D )) N2 51 6.4 ± 5.1 † K-ammonium acetate precipitation protocol (19) . Microsatellite markers (20) were amplified using 1 μL DNA (∼100 ng) using standard conditions (19) . The products were separated by electrophoresis through acrylamide gels. B6FVB-Tg(Ela-KRAS G12D ) F2 and FVB(B6FVB-Tg(Ela-KRAS G12D )F1) N2, D2FVB-Tg (Ela-KRAS G12D )F2 and FVB(D2FVB-Tg(Ela-KRAS G12D )F1) N2, and BALBFVB-Tg(Ela-KRAS G12D )F2 and FVB(BALBFVB-Tg (Ela-KRAS G12D )F1) N2 progeny were genotyped at ∼80 markers spanning the mouse genome ( Supplementary Table S2 ).
Linkage analysis
We used a nonparametric approach to assess linkage between the marker loci and the quantitative trait loci (QTL) that determine lesion multiplicity (21) . The data for each marker were analyzed for F2 and N2 mice using the Jonckheere-Terpstra and Wilcoxon rank sum tests, respectively, to obtain the test statistic Z W (22) . Genome-wide P values were estimated by permutation of the phenotype data (100,000 permutations for each cross) using Qlink 3.2 (19) . For each permutation, the most extreme test statistic (Z W ) was obtained and this distribution was used to determine the genome-wide significance level (23) . Minor QTL were identified by a conditional permutation test, in which lesion data at each marker were stratified according to the genotype at the major QTL. This secondary QTL analysis should also identify interactions between the major and minor loci. Equivalent LOD (logarithm of odds) scores, LOD W (21), were estimated as LOD W = 0.5 (log 10 e)(Z W ). The significance level for the overall hypothesis of linkage was determined using the method described by Fisher to combine data from F2 intercrosses and N2 backcrosses (24) . One-LOD support intervals for the loci identified in these analyses were estimated using R/qtl (25) .
RNA extraction and reverse transcription-PCR
Two separate methods were used. The first method used pancreatic tissue from F1 and consomic mice that was homogenized with Trizol (Invitrogen) according to the manufacturer's directions. RNA was visualized by ethidium bromide staining in 1% agarose gels. The absorbance ratio (260 nm/280 nm) for RNA was between 1.8 and 2.0. Reverse transcription was performed using the SuperScript II system (Invitrogen). Primers for the quantitative PCR of β-actin (control) and the KRAS/Kras cDNAs were designed with Primer3 software (Whitehead Institute for Biomedical Research, Cambridge, MA; Supplementary Table S3 ) based on the Kras and β-actin mRNA sequences (26) . Real-time quantitative PCR was performed on total cDNA using the SYBR Green Dye kit (Applied Biosystems) and the ABI 7700 (Applied Biosystems). Relative expression values were calculated as the amount of KRAS/Kras mRNA relative to β-actin and normalized to the expression in FVB mice.
An alternative technique was used for the analysis of the transgenic FVB and BALB consomic mice. In this method, which produced a higher-quality RNA from the pancreas, fresh pancreatic tissue (∼30 mg) from two mice of each strain was immediately homogenized in 1 mL of RLT Plus Buffer and 50 μL β-mercaptoethanol followed by RNA processing with the RNeasy Plus Mini kit with gDNA eliminator system (Qiagen, Inc.) according to the manufacturer's instructions. The Protoscript First-Strand system (New England BioLabs, Inc.) was used to perform reverse transcription reactions. The quality of the reverse transcription was assessed by quantitative PCR of the Gapdh gene using primers to the 3′, middle, and 5′ ends ( Supplementary Table S3 ). 3′ to 5′ ratios were quantified (27) and determined to be <5-fold using the IQ5 instrument and software (Bio-Rad Laboratories). OligoAnalyzer software v2.0 (IDT) was used to analyze KRAS/Kras mRNA sequences (26) and to identify and design primers that amplify the transgenic human KRAS gene and not the endogenous mouse Kras gene ( Supplementary Table S3 ). Reverse transcription-PCRs (RT-PCR) were carried out with total RNA using the SYBR Green Dye kit (ABgene). Relative expression values were calculated as the amount of the KRAS mRNA relative to the geometric mean of three housekeeping genes including Sdha, Ywhaz, and Actg1 (28).
Protein analysis
Protein was extracted from frozen pancreatic tissue using the TriPure Reagent (Roche). Protein (50 μg) was loaded and separated on Tris-tricine 10% to 20% 17-well PAGE gels (Fisher) and electrotransferred to nitrocellulose membranes (Osmonics). The membranes were incubated overnight with primary antibodies at 1:1,000 dilution to detect β-actin with goat anti-β-actin (Santa Cruz Biotechnology), Ras with rabbit anti-Ras (Cell Signaling), mitogen-activated protein kinase (MAPK) with antibody p44/42 (Cell Signaling), and phospho-MAPK with antibody p44/22 (Cell Signaling). Membranes were then incubated with horseradish peroxidase-linked goat antibiotin (Cell Signaling) or rabbit anti-IgG (Cell Signaling) secondary antibodies diluted at 1:1,000. Bands were detected using LumiGLO (Cell Signaling) for detection on film, and the ECL Western Blotting Detection kit (GE Healthcare) for analysis. Protein levels were quantified with the Phosphorimager and calculated as the amount of phospho-MAPK relative to β-actin.
Results
Genetic background affects pancreatic lesion multiplicity
To determine whether genetic background affects lesion multiplicity in Ela-KRAS G12D transgenics, we analyzed lesion multiplicity at 14 months in the male progeny of FVB-Tg (Ela-KRAS G12D ) males mated with C3, SW, B6, D2, or BALB females. Ductal lesions were counted in H&E-stained sections as described (16) . Except for the SW cross, the F1 progeny all showed an increase in the formation of ductal lesions relative to FVB-Tg(Ela-KRAS G12D ) mice ( Supplementary Table S1 ). Significant increases relative to FVB-Tg(Ela-KRAS G12D ) mice (0.3 ± 0.6) were identified in B6FVB-Tg(Ela-KRAS G12D )F1 (11 ± 5; 37-fold effect), D2FVB-Tg(Ela-KRAS G12D )F1 (8 ± 4; 27-fold effect), BALBFVB-Tg(Ela-KRAS G12D )F1 (8 ± 4; 27-fold effect), and C3FVB-Tg(Ela-KRAS G12D )F1 (4 ± 4, 13-fold effect) mice. SWFVB-Tg (Ela-KRAS G12D )F1 (0.6 ± 1) mice were similar to FVB transgenic mice in susceptibility.
Modifier loci map to chromosomes 2, 4, and 12
Crosses between B6, BALB, or D2 mice and FVB transgenic mice were used to map QTLs through linkage analysis of intercross (F2) and backcross (N2) mice sacrificed at 12 months. These mice were housed and analyzed separately from those in the preliminary F1 screen described above. The F1 mice in the linkage study developed more lesions but revealed the same relative susceptibilities of the inbred strains. The mean pancreatic lesion multiplicity of control in 12-monthold FVB-Tg(Ela-KRAS G12D ) mice was 1.6 ± 1.5 ( Table 1 ). The increase in lesion multiplicity in F1 mice at 12 months ranged from 7-fold in BALBFVB-Tg(Ela-KRAS G12D )F1 mice to 9-fold in B6FVB-Tg(Ela-KRAS G12D )F1 and D2FVB-Tg(Ela-KRAS G12D ) F1 mice (Table 1) . F1 mice were intercrossed or backcrossed to FVB. Intercross mice developed 7-to 11-fold Table 3 . B6-Chr Y FVB-Tg(Ela-KRASG12D) and BALB-Chr Y FVB-Tg(Ela-KRASG12D) consomic mice develop a significantly larger number of lesions than FVB-Tg(Ela-KRAS G12D )
Mouse strain
No. mice Lesion multiplicity ± SD FVB-Tg(Ela-KRAS G12D ) 32 2.8 ± 1.6 B6-Chr Y FVB-Tg(Ela-KRASG12D) 32 11 ± 6.4* BALB-Chr Y FVB-Tg(Ela-KRASG12D) 30 28 ± 13* more lesions, on average, than control FVB-Tg(Ela-KRAS G12D ) mice (Table 1) . Backcross progeny exhibited intermediate (4-to 6-fold) increases in the multiplicity of lesions relative to FVB-Tg(Ela-KRAS G12D ) ( Table 1) .
To map major QTLs, intercross and backcross genotype data at markers spanning the mouse genome and lesion phenotype data were assessed for linkage using a nonparametric permutation test. Markers on chromosomes 2, 4, and 12 segregated with lesion multiplicity and were designated Prsq1-3, Prsq4-5, and Prsq6, respectively. The combined LOD W scores for the backcross and intercross mice are shown in Fig. 1 .
The three Prsq loci on chromosome 2 map to the distal third of the chromosome. Prsq1 was identified in B6 × FVB crosses and is most significantly linked to D2Mit62 at 118 Mb (P < 0.006, F2; P < 0.016, N2; Table 2 ). The B6 Prsq1 allele is a semidominant susceptibility allele relative to FVB (2.7-fold effect). Prsq2 was linked to D2Mit51 at 163 Mb in the BALB × FVB backcross (P < 0.023, N2). In the BALB × FVB intercross, the same marker was linked to a similar, but not significant, effect. The BALB allele of Prsq2 confers susceptibility relative to FVB (2.3-fold effect). Prsq3 was mapped to D2Mit148 at 179 Mb in the D2 × FVB intercross (P < 0.039, F2). The D2 Prsq3 allele causes susceptibility relative to FVB (3.3-fold effect) and it is recessive, consistent with its lack of effect in the backcross. The one-LOD support interval for Prsq2 (BALB, 142-164 Mb) is contained entirely within that for Prsq1 (B6, 114-174 Mb; Supplementary Fig. S1 ). The interval for the Prsq3 (D2, 162-179 Mb) locus overlaps the distal end of the Prsq1-2 support interval. Because of the limited overlap of its one-LOD support interval and the smaller effect of the Prsq3 locus, further characterization of the chromosome 2 modifiers focused on those carried by B6 and BALB.
Prsq4 is linked to chromosome 4 near 63 Mb in the B6 × FVB intercross (P < 0.0002, F2; Table 2 ). A similar, but not significant, trend in lesion multiplicity was observed in the B6 × FVB backcross. The B6 Prsq4 allele is a semidominant resistance allele relative to FVB (2.9-fold effect). Prsq5 is linked to the same marker in the BALB × FVB intercross (P < 0.016 F2). The BALB allele causes susceptibility relative to FVB (2.8-fold effect) and it is recessive, consistent with its lack of effect in the backcross. The one-LOD support interval for Prsq4 (B6, 58-81 Mb) is contained within that for Prsq5 (BALB, 54-125 Mb; Supplementary Fig. S1 ). Lesion multiplicity was not significantly linked to the Prsq4-5 region in the D2 F2 or N2 crosses (data not shown).
Prsq6 is linked to D12Mit5 near 82 Mb (one-LOD support interval, 19-105 Mb) on chromosome 12 in the FVB × BALB backcross (P < 0.046; Table 2 ). The FVB allele is the susceptible allele (1.9-fold effect; Table 2 ). Prsq6 was not identified in the F2 analysis; any effect may be obscured by the Prsq2 and Prsq5 effects.
Haplotype analysis for the Prsq1-2 and Prsq4-5 intervals
We performed a preliminary analysis of the single-nucleotide polymorphisms (SNP) carried by the FVB, B6, and BALB strains within the combined one-LOD support intervals for Prsq1-2 and Prsq4-5 using data from the Mouse HapMap Imputed Genotype Resource ( Supplementary Fig. S1; ref. 29 ). These broad intervals (∼60-70 Mb each) contain large numbers of genes (1,011 and 977 for chromosomes 2 and 4, respectively). B6 and BALB carry alleles on chromosome 2 that confer susceptibility relative to FVB; on chromosome 4, B6 and BALB carry alleles with opposite effects. Therefore, the simplest models for the haplotype patterns among these strains are that B6 and BALB share haplotypes distinct from that of FVB on chromosome 2 (Prsq1-2) and that FVB, B6, and BALB all differ from one another in haplotype on chromosome 4 (Prsq4-5). Under these models, the numbers of potential candidates for the susceptibility loci are limited to 126 and 287 genes ( Supplementary Table S4 ) for Prsq1-2 and Prsq4-5, respectively. Under the hypothesis that each locus is unique (e.g., the B6 allele of Prsq1 differs from both the FVB and BALB alleles, which may be the same), the number of candidates within the one-LOD support intervals for Prsq1, Prsq2, Prsq4, and Prsq5 includes 654, 164, 138, and 535 genes, respectively.
Inbred B6 and BALB mice consomic for the Ela-KRAS G12Dtransgenic Y chromosome are more susceptible than FVB
The Ela-KRAS G12D transgene in this mouse model is located on the Y chromosome. By repeatedly backcrossing B6FVB-Tg(Ela-KRAS G12D )F1 to B6 mice, and BALBFVB-Tg (Ela-KRAS G12D )F1 to BALB mice, we have developed mice that are consomic for the FVB Y chromosome carrying the Ela-KRAS G12D transgene on either a B6 or BALB genetic background (n ≥ 10). Analysis of B6-Chr Y FVB-Tg(Ela-KRASG12D) and BALB-Chr Y FVB-Tg(Ela-KRASG12D) consomic mice at 12 months of age revealed the development of a significantly larger number of lesions relative to FVB-Tg(Ela-KRAS G12D ) mice ( Table 3) . We found a 4-fold increase in mean lesion multiplicity in B6-Chr Y FVB-Tg(Ela-KRASG12D) (11.1 ± 6.4) and a 10-fold increased effect in BALB-Chr Y FVB-Tg(Ela-KRASG12D) (28 ± 13) relative to FVB-Tg(Ela-KRAS G12D ) (2.8 ± 1.6).
Histologic analysis of B6-Chr Y FVB-Tg(Ela-KRASG12D) and BALB-Chr Y FVB-Tg(Ela-KRASG12D) consomic mice revealed ducts containing irregular epithelial cells similar to those identified in the FVB-Tg(Ela-KRAS G12D ) mice (16) . Focal carcinomas of mixed morphologic differentiation (acinar and/or ductal characteristics) were identified in ∼13% of FVB-Tg(Ela-KRAS G12D ) (4 of 32 mice), ∼22% of B6-Chr Y FVB-Tg(Ela-KRASG12D) (7 of 32 mice), and ∼60% of BALB-Chr Y FVB-Tg(Ela-KRASG12D) (18 of 30 mice). Mouse PanINs (mPanIN; ref. 11) have projections of papillary epithelium into the lumens of ducts and are the potential precursors to invasive ductal adenocarcinoma in mice. Such projections were more frequent in the B6-Chr Y FVB-Tg(Ela-KRASG12D) and BALB-Chr Y FVB-Tg(Ela-KRASG12D) consomic mice (Fig. 2) relative to FVB-Tg(Ela-KRAS G12D ) mice.
Notably, invasive ductal adenocarcinomas penetrating the basement membrane were identified in ∼10% of the BALB-Chr Y FVB-Tg(Ela-KRASG12D) (3 of 30 mice; Fig. 2 ). Rare invasive ductal adenocarcinomas have been identified in FVB-Tg(Ela-KRAS G12D ) mice at time points later than 12 months of age. 3 In these studies at 12 months of age, the BALB-Chr Y FVB-Tg(Ela-KRASG12D) strain was the only consomic line to develop invasive ductal adenocarcinomas.
KRAS/Kras mRNA and protein levels are similar in FVB, B6, and BALB strains RT-PCR analysis using RNA from frozen tissue revealed similar levels for the total amount of KRAS/Kras mRNA (from transgenic human and endogenous mouse genes) across the FVB-Tg(Ela-KRAS G12D ), B6-Chr Y FVB-Tg(Ela-KRASG12D) , and BALB-Chr Y FVB-Tg(Ela-KRASG12D) consomic strains. KRAS/Kras and β-actin mRNA from six, seven, or nine animals (B6, BALB, and FVB, respectively) were quantitated, and the expression of KRAS/Kras mRNA relative to β-actin was determined. KRAS/ Kras expression in B6 and BALB did not differ significantly from FVB (P > 0.42, B6 versus FVB; P > 0.37, BALB versus FVB; Supplementary Fig. S2 ). RT-PCR analysis using RNA isolated immediately from fresh tissue revealed similar levels of transgenic (human) KRAS mRNA for FVB-Tg(Ela-KRAS G12D ) and BALB-Chr Y FVB-Tg(Ela-KRASG12D) consomic mice. The expression of the transgenic KRAS mRNA relative to the geometric mean of Sdha, Ywhaz, and Actg1 was 0.039 ± 0.030 for FVB-Tg(Ela-KRAS G12D ) and 0.028 ± 0.001 for BALB-Chr Y FVB-Tg(Ela-KRASG12D) consomics. In addition, there was a <2-fold difference in KRAS expression between FVB-Tg (Ela-KRAS G12D ) and FVB B6-Chr Y FVB-Tg(Ela-KRASG12D) F1 hybrid animals. Consistent with these findings, we were not able to detect differences in KRAS/Kras mRNA levels among F1 progeny (data not shown). Human KRAS expression was not detected in nontransgenic mice.
Similarly, we did not detect a significant difference in levels of Ras or phospho-MAPK protein expression across strains by Western blot (P > 0.18; Fig. 3 ). The relative amounts of the p42 and p44 isoforms were variable between experiments and did not correlate with susceptibility. Consistent with these findings among consomics, we were not able to detect differences in phospho-MAPK expression among F1 progeny (data not shown). 
Discussion
Linkage analysis identified Prsq1-3, Prsq4-5, and Prsq6 on chromosomes 2, 4, and 12, respectively, as the predominant modifiers of lesion multiplicity in Ela-KRAS G12D mice. The Prsq1-3 loci on chromosome 2 in B6, BALB, and D2 mice confer susceptibility relative to FVB. The B6 allele of Prsq1 is semidominant. Dominance of the BALB allele of Prsq2, which had no significant effect in the intercross, could not be assessed. The D2 allele of Prsq3 is recessive. Prsq4 and Prsq5 on chromosome 4 have opposite effects in B6 and BALB relative to FVB. The B6 allele of Prsq4 is semidominant and confers resistance, whereas the BALB allele of Prsq5 is recessive and confers susceptibility. Prsq6 was found on chromosome 12; the BALB allele conferred resistance in the backcross only. The effects of Prsq1-6 are unlikely to be due to differences in transgene expression: RT-PCR and Western blot analysis determined that levels of transgene expression are similar among the inbred consomic strains and the backcross and intercross progeny.
More detailed analysis may reveal multiple modifier genes within the Prsq loci. The identification of multiple modifiers within QTLs has been documented in intestinal and breast cancer and plasmacytoma, where multiple syntenic genetic elements influence susceptibility (30) (31) (32) . The generation of congenic strains and fine-mapping of the loci should help determine the number of genes that underlie these QTLs.
The overlapping one-LOD support intervals for Prsq1-3 on chromosome 2, and for Prsq4-5 on chromosome 4, suggest that these syntenic loci might be related. However, the location of peak linkage differs for Prsq1-3, as does dominance of the B6 and D2 alleles of Prsq1 and Prsq3 relative to FVB. For Prsq4-5, peak linkage maps to the same marker, but the direction of the effects of the B6 and BALB alleles differs, as does dominance relative to FVB. The relationships among these loci-whether they correspond to different alleles of the same genes, subsets of the same gene clusters, or unrelated genes-should be revealed on further mapping and eventual cloning of the responsible genes.
The construction of consomic B6 and BALB strains carrying the KRAS-transgenic FVB Y chromosome allowed us to assess the effects of Prsq modifiers in the absence of autosomal FVB alleles. B6-Chr Y FVB-Tg(Ela-KRASG12D) consomic mice developed 11.8 ± 6.4 lesions, 4-fold more than FVB-Tg(Ela-KRAS G12D ) mice. The lesion multiplicity of Prsq1 B6/B6 Prsq4 B6/B6 mice in the F2 cross was 11.8 ± 2.6. This similarity suggests that Prsq1 and Prsq4 together account for all of the phenotype of B6 consomic mice relative to FVB. BALB-Chr Y FVB-Tg(Ela-KRASG12D) consomic mice developed 28 ± 13 lesions, 10-fold more than FVB-Tg(Ela-KRAS G12D ) mice. The lesion multiplicity in Prsq2 BALB/BALB Prsq5 BALB/BALB mice in the F2 cross was 33 ± 16. This similarity suggests that Prsq2 and Prsq5 account for the susceptibility of BALB consomic mice relative to FVB. The consomic strains will be helpful in the analysis of congenic strains carrying Prsq loci on B6 or BALB backgrounds. In addition, their development of invasive lesions at a relatively young age (12 months) should make the BALB consomics useful in the study of more advanced stages of pancreatic cancer.
Haplotype analysis identified many genes consistent with the simplest models for the chromosome 2 and 4 loci. The 126 genes on chromosome 2 that are candidates for both Prsq1 and Prsq2 include 11 involved in transcription, 10 involved in development, and 9 involved in cell differentiation. These candidates include the TGFβ family member Bmp2, the Rb family member p107, C/EBP, and the Notch ligand gene jagged 1. The 287 genes on chromosome 4 that are candidates for both Prsq4 and Prsq5 include 23 involved in transcription, 21 involved in development, and 16 involved in signal transduction. These chromosome 4 candidates include Deleted in Bladder Cancer 1, Mycbp, and the Ras gene family member Rab3b. Gene expression and mapping analysis of congenic lines carrying defined portions of chromosomes 2 and 4 will be needed to reduce the large numbers of candidates for each locus and allow testing by transgenesis or gene replacement.
Analysis of the genomic locations of the Prsq loci also revealed candidates that have already been implicated as having effects on pancreatic tumorigenesis (3, 8, 12, (33) (34) (35) (36) . One possible Prsq1-3 candidate gene near 172 Mb on chromosome 2, within the one-LOD support intervals for Prsq1 and Prsq3, is Aurka. The B6, BALB, and D2 strains share a SNP haplotype for this gene that differs from that for FVB. Overexpression of an oncogenic version of Aurka causes mild pancreatic duct dysplasia (33) . However, expression of Aurka mRNA relative to FVB (set at 1.0) among susceptible strains carrying the KRAS transgene varied and was 3.6 for B6 and 0.8 for BALB (data not shown). Although these results do not support Aurka as a candidate for Prsq2, they are consistent with the possibility that elevated Aurka expression in B6 accounts for some or all of the Prsq1 effect.
Two candidates for the Prsq4-5 loci on mouse chromosome 4 (peak LOD W score at 63.0 Mb) are Tgfbr1 and Cdkn2a, at 47.4 and 88.9 Mb, respectively. Alterations in CDKN2A/Cdkn2a and . Comparable transgene expression levels in FVB, B6, and BALB strains. Western blots of protein levels from two pools of three animals each for each consomic Ela-KRAS G12D strain were analyzed. Amounts of phospho-extracellular signal-regulated kinase (P-ERK) were quantified and normalized to β-actin. The level of P-ERK relative to that in FVB is shown. P-ERK was not detected in the nontransgenic animals (data not shown). TGFBR1/Tgfbr1 signaling have been found to have an effect on pancreatic cancer progression in mice and also have been observed in human PDAC (3, 8, 12, (34) (35) (36) . Tgfbr1 is well outside the one-LOD support intervals for Prsq4-5. However, because of the strong data supporting a role for transforming growth factor-β (TGF-β) signaling in pancreatic cancer in both humans and mice, D4Mit6 (50.0 Mb) was used to assess directly linkage of the more proximal modifier, Prsq4, to Tgfbr1 (47.4 Mb) in B6FVB-Tg(Ela-KRAS G12D )F2 mice. Results were compared with those for the most significant marker for Prsq4, where there is a 2.9-fold effect of B6 alleles. There was no effect at D4Mit6 near Tgfbr1, indicating that this gene is not likely to be Prsq4.
Several observations make Cdkn2a an appealing candidate for Prsq5. First, Cdkn2a is near the midpoint of the interval between D4Mit17 (63 Mb) and D4Mit31 (107 Mb), both of which yielded high LOD W scores (2.84 and 2.45, respectively) in the BALB × FVB F2 cross. Second, we have observed that Ela-KRAS transgenic mice heterozygous for p16-null mutations develop pancreatic ductal tumors with greatly reduced latency and frequent metastasis relative to p16 wild-type mice. 4 Finally, the BALB allele of Cdkn2a has been shown to be hypomorphic for p16 function (32, 37) . Analysis of SNPs within the Cdkn2a gene (29) indicates that the BALB haplotype is unique among the four strains we studied; FVB and B6 mice have identical SNP haplotypes for this gene.
Prsq1-3 and Prsq4-5 correspond to two of the human chromosomal regions that are most frequently gained or lost in pancreatic cancer (38, 39) . Part of the region of peak linkage for Prsq1-3 (152-179 Mb) on chromosome 2 corresponds to human 20q11-13, which carries AURKA and is amplified in approximately half of pancreatic cancers (38, 39) . Human chromosome 9p, which carries CDKN2A and corresponds to part of the Prsq4-5 region on chromosome 4, is lost in approximately half of pancreatic cancers (38, 39) .
The close correspondence between predominant human chromosomal changes and the Prsq loci indicates that further study of the mouse modifiers is likely to help explain the development of pancreatic cancer in humans. The development of congenic lines for the Prsq loci will allow investigation of biological mechanisms and the roles they play in pancreatic cancer progression. Additionally, such lines will allow the individual and additive effects of the loci to be analyzed, provide a framework for detailed physical mapping, and, ultimately, facilitate positional cloning of genes within these regions. The molecular identification of modifier genes in the mouse model should facilitate the search for human susceptibility genes and the identification of populations that might be predisposed to PDAC.
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